

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

Claim 1 (withdrawn): A method for treatment of neurodegenerative conditions and effects of aging, including autoimmune conditions and fibromyalgia, said method comprising the steps of:

administering to a patient a compound effective for increasing neuronal metabolism of histamine to a histamine H<sub>2</sub> agonist, in an amount sufficient that said histamine H<sub>2</sub> agonist is produced in an amount adequate to stimulate production of cyclic AMP at a level which maintains myelin against undergoing self-degeneration;

the step of administering said compound comprising administering histamine N-methyltransferase to said patient so as to increase neuronal metabolism of histamine to tele-methylhistamine.

Claims 2-3 (cancelled)

Claim 4 (withdrawn): The method of claim 1, wherein the step of administering histamine N-methyltransferase comprises:

Administering isolated histamine N-methyltransferase by injection.

Claims 5-17 (cancelled)

Claim 18 (currently amended): A method for therapeutic treatment of neurodegenerative, multiple sclerosis related conditions and effects of aging, including autoimmune conditions and fibromyalgia, said method comprising the steps of:

administering to a patient a compound effective for increasing neuronal metabolism of histamine to a histamine H<sub>2</sub> agonist, in an amount sufficient that said histamine H<sub>2</sub> agonist is produced in an amount adequate to stimulate production of cyclic AMP at a level which maintains myelin against undergoing self-degeneration;

the step of administering said compound comprising administering monoamine oxidase-A to said patient in accordance with a regimen that provides a predetermined daily dosage of said monoamine oxidase-A so as to increase neuronal metabolism of tele-methylhistamine to an H<sub>2</sub> agonist

Claim 19 (withdrawn): A method for treatment of neurodegenerative conditions and effects of aging, including autoimmune conditions and fibromyalgia, said method comprising the steps of:

administering to a patient a compound effective for increasing neuronal metabolism of histamine to a histamine H<sub>2</sub> agonist, in an amount sufficient that said histamine H<sub>2</sub> agonist is produced in an amount adequate to stimulate production of cyclic AMP at a level which maintains myelin against undergoing self-degeneration;

the step of administering a compound comprising administering a histamine H<sub>3</sub> antagonist to said patient so as to inhibit neuronal metabolism of tele-methylhistamine to an H<sub>3</sub> antagonist and thereby increase neuronal metabolism of tele-methylhistamine to an H<sub>2</sub> agonist.

Claim 20 (withdrawn): The method of claim 19, wherein said histamine H<sub>3</sub> antagonist is thioperamide maleate.

Claim 21 (currently amended): A method for therapeutic treatment of neurodegenerative, multiple sclerosis related conditions and effects of aging, including autoimmune conditions and fibromyalgia, said method comprising the steps of:

administering to a patient a compound effective for increasing neuronal metabolism of histamine to a histamine H<sub>2</sub> agonist, in an amount sufficient that said histamine H<sub>2</sub> agonist is produced in an amount adequate to stimulate production of cyclic AMP at a level which maintains myelin against undergoing self-degeneration;

the step of administering said compound comprising administering a monoamine oxidase-A agonist to said patient in accordance with a regimen that provides a predetermined daily dosage of said monamine oxidase-A agonist so as to increase neuronal metabolism of tele-methylhistamine to an H<sub>2</sub> agonist.

Claim 22 (previously added): The method of claim 21, wherein said monoamine oxidase-A agonist is reserpine.

Claim 23 (previously added): The method of claim 22, wherein the step of administering said monoamine oxidase-A agonist comprises:

administering reserpine by slow-release transdermal dose.

Claim 24 (previously added): The method of claim 21, wherein the step of administering said monoamine oxidase-A agonist comprises:

administering reserpine by injection in the range from about 1-10 mg/kg S.C. per day.